What is Centogene?
Centogene N.V. operates as a global provider of pharmaceutical solutions and diagnostic tests, serving markets across Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company specializes in delivering data-driven insights for rare and neurodegenerative diseases, aiding patients, physicians, and pharmaceutical partners. Its offerings include the CENTOGENE MOx 2.0 multiomic solution, the CentoCloud SaaS platform for genomic variant analysis, and the NEW CentoGenome NGS assay, all designed to expedite access to potential treatment options for complex genetic conditions.
How much funding has Centogene raised?
Centogene has raised a total of $146M across 4 funding rounds:
Series A
$28M
Stock Offering
$56M
Debt
$45M
Share Placement
$17M
Series A (2017): $28M with participation from Careventures, TVM Capital, and Deutsche Private Equity
Stock Issuance/Offering (2019): $56M led by Undisclosed
Debt (2022): $45M supported by Oxford Finance
Share Placement (2022): $17M featuring Careventures, TVM Capital, and Deutsche Private Equity
Key Investors in Centogene
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide.
Careventures
Careventures is an independent pan-European private equity firm dedicated to improving healthcare through smart investments, partnering with middle-market healthcare companies to foster growth and innovation.
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm focused on investing in innovative life science products and companies, providing capital and expertise to support breakthrough therapies.
What's next for Centogene?
The recent major strategic investment signifies Centogene's robust trajectory and its capacity to attract significant capital for expansion and innovation. This financing is poised to bolster its research and development efforts, enhance its diagnostic capabilities, and potentially expand its global reach. The company's focus on rare and neurodegenerative diseases positions it within a critical and growing segment of the healthcare industry, suggesting a strategic push towards further market penetration and the development of novel therapeutic avenues.
See full Centogene company page
